SCHEMBL733287

SCHEMBL733287

CN(C)C1(c2ccccc2)CC=C(c2c[nH]c3ncccc23)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
DYRK1A Q13627 4/20 0.43
PIM1 P11309 4/20 0.41
PRKACA P17612 4/20 0.41
GSK3B P49841 4/20 0.41
CDK2 P24941 3/20 0.41
HIPK2 Q9H2X6 3/20 0.41
IRAK4 Q9NWZ3 3/20 0.41
MAP4K4 O95819 3/20 0.41
CLK4 Q9HAZ1 3/20 0.41
CDK1 P06493 2/20 0.41
ROCK2 O75116 2/20 0.41
CHEK1 O14757 2/20 0.41
CLK2 P49760 2/20 0.41
CDK5 Q00535 2/20 0.41
PRKAA1 Q13131 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930943 0.92 DYRK1A (0.42) TMEM97SIGMAR1HTR2AHTR2CHTR2B
Citric Acid SCHEMBL735516 0.87 DYRK1A (0.41) TMEM97SIGMAR1HTR2AHTR2CHTR2B
Citric Acid SCHEMBL735515 0.87 DYRK1A (0.41) TMEM97SIGMAR1HTR2AHTR2CHTR2B
SCHEMBL733637 0.82 SLC6A4 (0.51) HTR2AHTR2COPRM1OPRL1OPRK1
SCHEMBL734778 0.80 TMEM97 (0.50) TMEM97SIGMAR1HTR2AHTR2CHTR2B
SCHEMBL734100 0.79 OPRM1 (0.40) OPRM1OPRL1OPRK1
SCHEMBL735452 0.76 RIPK1 (0.41) CDK1OPRM1OPRL1OPRK1CCNB2
SCHEMBL733282 0.75 TMEM97 (0.46) TMEM97SIGMAR1HTR2AHTR2CHTR2B
SCHEMBL734179 0.74 OPRM1 (0.37) OPRM1OPRL1
Hydrochloric Acid SCHEMBL25428554 0.72 HTR2A (0.51) TMEM97SIGMAR1HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044016-B1 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM GRUENENTHAL GMBH (DE) 2012-12-05 EP claimed
US-8138187-B2 Substituted heteroaryl derivatives GRUENENTHAL GMBH (DE) 2012-03-20 US claimed
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES GRUNENTHAL GMBH (DE) 2010-01-14 US claimed
EP-2044016-A2 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM Grünenthal GmbH (DE) 2009-04-08 EP claimed
WO-2008009415-A2 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM Grünenthal GmbH (DE) 2008-01-24 WO claimed
EP-2044016-B1 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM GRUENENTHAL GMBH (DE) 2012-12-05 EP disclosed
US-8138187-B2 Substituted heteroaryl derivatives GRUENENTHAL GMBH (DE) 2012-03-20 US disclosed
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES GRUNENTHAL GMBH (DE) 2010-01-14 US disclosed
EP-2044016-A2 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM Grünenthal GmbH (DE) 2009-04-08 EP disclosed
WO-2008009415-A2 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1- AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM Grünenthal GmbH (DE) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009986-A1 SUBSTITUTED HETEROARYL DERIVATIVES CYP3A43, HMGCR, ABCG2 TMEM97 1414/4885SIGMAR1 873/4885HTR2A 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.